trial · primary record
Luspatercept
Myelodysplastic Syndromes
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 75 |
| Primary completion | 2027-12-31 |
| Primary endpoint | Proportion of patients achieving red blood cell transfusion independence (RBC-TI) for at least 8 weeks |
| Registry ID | NCT07894861 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:32:33.498Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07894861
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.